Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment

Herget, Georg W.; Wäsch, Ralph; Klein, Lukas; Schmal, Hagen; Terpos, Evangelos; Engelhardt, Monika

doi:10.3324/haematol.2019.245423

Cited by 9 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous analyses suggested that diagnostic delays are associated with worse clinical outcomes [20][21][22][23][24][25]. A recent study reported that skeletal-related events (SRE) in newly diagnosed MM patients occur very frequently: two-thirds of patients had a SRE before study enrollment; additionally, 44% had at least one onstudy SRE, with 60% of all first SREs occurring within the first 3 months and 81% occurring within the first 6 months [26].…”

Section: Discussionmentioning

confidence: 99%

Interdisciplinary approach to multiple myeloma – time to diagnosis and warning signs

Herget

Kälberer

Ihorst

et al. 2020

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

Delayed diagnosis is a common challenge in the management of multiple myeloma (MM). This prospective interdisciplinary study evaluated symptoms and time to diagnosis (TTD) in 81/295 screened patients at our tertiary center, who were examined by an orthopedist prior to the MM diagnosis. The most frequent complaint was back pain (81%), mainly localized thoracic and/or lumbar. Pain was independent of movement in 85%, occurred at night in 69%, and at multiple localizations in 30% of patients. Notably, 63% patients with an orthopedic disease noticed substantial symptom change before the MM diagnosis was made. The median TTD was 7 months and did not differ significantly between patients with or without a preexisting skeletal disease. To avoid delayed diagnosis, physicians should consider MM as a differential diagnosis, whenever warning signs such as skeletal pain independent from movement, at night, at various localizations, and change in pain characteristics accompanied by fatigue, are reported.

show abstract

Section: Discussionmentioning

confidence: 99%

Interdisciplinary approach to multiple myeloma – time to diagnosis and warning signs

Herget

Kälberer

Ihorst

et al. 2020

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since most myeloma patients suffer from osteolytic lesions, bisphosphonates or denosumab should be administered regularly [91]. Medical care of myeloma patients with skeletal lesions should include close collaboration with radiologists, orthopedists and radiation oncologists [6,45,[91][92][93][94].…”

Section: Supportivesmentioning

confidence: 99%

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors

Gengenbach

Graziani

Reinhardt

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Treatment of relapsed/refractory multiple myeloma (RRMM) is more complex today due to the availability of novel therapeutic options, mostly applied as combination regimens. immunotherapy options have especially increased substantially, likewise the understanding that patient-, disease- and treatment-related factors should be considered at all stages of the disease. RRMM is based on definitions of the international myeloma working group (IMWG) and includes biochemical progression, such as paraprotein increase, or symptomatic relapse with CRAB criteria (hypercalcemia, renal impairment, anemia, bone lesions). When choosing RRMM-treatment, the biochemical markers for progression and severity of the disease, dynamic of disease relapse, type and number of prior therapy lines, including toxicity and underlying health status, need to be considered, and shared decision making should be pursued. Objectively characterizing health status via geriatric assessment (GA) at each multiple myeloma (MM) treatment decision point has been shown to be a better estimate than via age and comorbidities alone. The well-established national comprehensive cancer network, IMWG, European myeloma network and other national treatment algorithms consider these issues. Ideally, GA-based clinical trials should be supported in the future to choose wisely and efficaciously from available intervention and treatment options in often-older MM adults in order to further improve morbidity and mortality.

show abstract

“…Sensitive, simple, and rapid diagnostic methods play a decisive role in the treatment of chronic diseases [44][45][46]. Early diagnosis and treatment of disease can significantly reduce mortality and human suffering [47,48]. Diseases can be detected by monitoring a variety of disease-related "biomarkers", which are substances or activities that can be detected and evaluated [49,50].…”

Section: Introductionmentioning

confidence: 99%

Recent advances on portable photoelectrochemical biosensors for diagnostics

Wu,

Tang

2023

Electroanalysis

View full text Add to dashboard Cite

Efficient and accurate diagnostic methods are important for human health monitoring and prevention of major diseases, so the establishment of efficient and convenient testing methods for clinical diagnosis is urgent. Photoelectrochemical (PEC) biosensors have attracted much attention because of their high sensitivity, low detection background, and especially the advantages of combining photoexcitation and electrochemical detection. With the rapid development of integrated circuit technology many wireless transmissions of highly aggregated portable micro devices are manufactured, its small size, easy to carry, and the ability to visualize the results of the test is shown to be the potential for the application of such devices. This review aims to cover recent advances in PEC biosensing within the field of portable detection, including the principles of PEC biosensors, common photovoltaic materials, and scalable fabrication techniques for portable PEC biosensing. Future prospects in the field are also discussed.

show abstract

Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment

Cited by 9 publications

References 22 publications

Interdisciplinary approach to multiple myeloma – time to diagnosis and warning signs

Interdisciplinary approach to multiple myeloma – time to diagnosis and warning signs

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors

Recent advances on portable photoelectrochemical biosensors for diagnostics

Contact Info

Product

Resources

About